SGLT ‐2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With MASH Cirrhosis and Type 2 Diabetes
- 27 December 2025
- journal article
- Published by Wiley in Liver International
- Vol. 46 (2) , e70490
Abstract
Introduction: Metabolic dysfunction‐associated steatotic liver disease (MASLD) and steatohepatitis (MASH) represent a spectrum of liver conditions that can gradually progress to cirrhosis. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors have shown benefits in reducing hepatic steatosis and liver‐related events in MASLD. This study aims to assess whether SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality and disease‐specific outcomes in patients with MASH cirrhosis and type 2 diabetes (T2D). Methods: A retrospective cohort study was performed using TriNetX. Patients with T2D and MASH cirrhosis on SGLT‐2 inhibitors were matched 1:1 with other glucose‐lowering drugs (oGLDs) based on demographics, comorbidities and medications. Primary outcomes included all‐cause mortality, hepatic decompensation and major adverse liver outcomes (MALO). Cox‐proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence interval (CI). Results: A total of 51 427 patients with MASH cirrhosis and T2D were identified, of which 6833 (13.28%) were on SGLT‐2 inhibitors. Patients on SGLT‐2 inhibitors ( n = 6449, mean age 63.7 years, 52.9% female) were matched with 6449 individuals (mean age 63.9 years, 53.5% female) on oGLDs. The SGLT‐2 inhibitors cohort had statistically significantly lower risk of all‐cause mortality (HR: 0.58, 95% CI: 0.53–0.63), hepatic decompensation (HR: 0.85, 95% CI: 0.81–0.90) and MALO (HR: 0.88, 95% CI: 0.83–0.93). Conclusion: SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality in patients with MASH cirrhosis and T2DM, which may be partly attributable to a lower risk of hepatic decompensation and subsequent events. Further studies are warranted as SGLT‐2 inhibitors may serve as an adjunctive therapy for patients with MASH cirrhosis.Keywords
This publication has 31 references indexed in Scilit:
- Sodium-Glucose Cotransporter 2 Inhibitors and Serious Liver Events in Patients With CirrhosisJAMA Network Open, 2025
- The Liver in Diabetes and Metabolic SyndromeClinics in Liver Disease, 2025
- High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: A Meta-analysisClinical Gastroenterology and Hepatology, 2025
- Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050JAMA Network Open, 2025
- Diabetes as a risk factor for MASH progressionDiabetes Research and Clinical Practice, 2024
- SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activationCell Metabolism, 2024
- Liver fibrosis emulation: Impact of the vascular fibrotic alterations on hemodynamicsComputers in Biology and Medicine, 2023
- Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLDHepatology Communications, 2021
- Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2021
- EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosisJournal of Hepatology, 2010